Alvotech shares drop after $152 million equity financing; existing holders face dilution
Alvotech said it has raised about $152 million through a priced public offering and a concurrent private placement, moves that coincided with an 8.7% decline in its shares and add meaningful dilution given the company’s roughly 312 million shares outstanding. The Reykjavik, Iceland-based biosimilar developer will direct net proceeds toward its bios…